IBDEI2AP ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,38939,1,3,0)
 ;;=3^SCC Skin Overlapping Sites
 ;;^UTILITY(U,$J,358.3,38939,1,4,0)
 ;;=4^C44.82
 ;;^UTILITY(U,$J,358.3,38939,2)
 ;;=^5001089
 ;;^UTILITY(U,$J,358.3,38940,0)
 ;;=L57.8^^151^1906^22
 ;;^UTILITY(U,$J,358.3,38940,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38940,1,3,0)
 ;;=3^Skin Changes d/t Chr Exposure to Nonionizing Radiation
 ;;^UTILITY(U,$J,358.3,38940,1,4,0)
 ;;=4^L57.8
 ;;^UTILITY(U,$J,358.3,38940,2)
 ;;=^5009226
 ;;^UTILITY(U,$J,358.3,38941,0)
 ;;=L27.0^^151^1906^23
 ;;^UTILITY(U,$J,358.3,38941,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38941,1,3,0)
 ;;=3^Skin Eruption,Generalized d/t Drugs/Meds Taken Internally
 ;;^UTILITY(U,$J,358.3,38941,1,4,0)
 ;;=4^L27.0
 ;;^UTILITY(U,$J,358.3,38941,2)
 ;;=^5009144
 ;;^UTILITY(U,$J,358.3,38942,0)
 ;;=L27.1^^151^1906^24
 ;;^UTILITY(U,$J,358.3,38942,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38942,1,3,0)
 ;;=3^Skin Eruption,Localized d/t Drugs/Meds Taken Internally
 ;;^UTILITY(U,$J,358.3,38942,1,4,0)
 ;;=4^L27.1
 ;;^UTILITY(U,$J,358.3,38942,2)
 ;;=^5009145
 ;;^UTILITY(U,$J,358.3,38943,0)
 ;;=L51.1^^151^1906^29
 ;;^UTILITY(U,$J,358.3,38943,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38943,1,3,0)
 ;;=3^Stevens-Johnson Syndrome
 ;;^UTILITY(U,$J,358.3,38943,1,4,0)
 ;;=4^L51.1
 ;;^UTILITY(U,$J,358.3,38943,2)
 ;;=^336636
 ;;^UTILITY(U,$J,358.3,38944,0)
 ;;=L51.3^^151^1906^30
 ;;^UTILITY(U,$J,358.3,38944,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38944,1,3,0)
 ;;=3^Stevens-Johnson Syndrome-Toxic Epdrml Necrolysis Overlap Syndrome
 ;;^UTILITY(U,$J,358.3,38944,1,4,0)
 ;;=4^L51.3
 ;;^UTILITY(U,$J,358.3,38944,2)
 ;;=^336637
 ;;^UTILITY(U,$J,358.3,38945,0)
 ;;=Z12.83^^151^1906^19
 ;;^UTILITY(U,$J,358.3,38945,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38945,1,3,0)
 ;;=3^Screening for Malig Neop of Skin
 ;;^UTILITY(U,$J,358.3,38945,1,4,0)
 ;;=4^Z12.83
 ;;^UTILITY(U,$J,358.3,38945,2)
 ;;=^5062696
 ;;^UTILITY(U,$J,358.3,38946,0)
 ;;=Z48.817^^151^1906^33
 ;;^UTILITY(U,$J,358.3,38946,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38946,1,3,0)
 ;;=3^Surgical Aftercare Following Skin Surgery
 ;;^UTILITY(U,$J,358.3,38946,1,4,0)
 ;;=4^Z48.817
 ;;^UTILITY(U,$J,358.3,38946,2)
 ;;=^5063054
 ;;^UTILITY(U,$J,358.3,38947,0)
 ;;=L94.0^^151^1906^18
 ;;^UTILITY(U,$J,358.3,38947,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38947,1,3,0)
 ;;=3^Scleroderma,Localized
 ;;^UTILITY(U,$J,358.3,38947,1,4,0)
 ;;=4^L94.0
 ;;^UTILITY(U,$J,358.3,38947,2)
 ;;=^5009470
 ;;^UTILITY(U,$J,358.3,38948,0)
 ;;=D23.9^^151^1906^20
 ;;^UTILITY(U,$J,358.3,38948,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38948,1,3,0)
 ;;=3^Sebaceous Hyperplasia
 ;;^UTILITY(U,$J,358.3,38948,1,4,0)
 ;;=4^D23.9
 ;;^UTILITY(U,$J,358.3,38948,2)
 ;;=^5002076
 ;;^UTILITY(U,$J,358.3,38949,0)
 ;;=L21.9^^151^1906^21
 ;;^UTILITY(U,$J,358.3,38949,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38949,1,3,0)
 ;;=3^Seborrhea,Unspec
 ;;^UTILITY(U,$J,358.3,38949,1,4,0)
 ;;=4^L21.9
 ;;^UTILITY(U,$J,358.3,38949,2)
 ;;=^188703
 ;;^UTILITY(U,$J,358.3,38950,0)
 ;;=L91.8^^151^1906^25
 ;;^UTILITY(U,$J,358.3,38950,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38950,1,3,0)
 ;;=3^Skin Tag
 ;;^UTILITY(U,$J,358.3,38950,1,4,0)
 ;;=4^L91.8
 ;;^UTILITY(U,$J,358.3,38950,2)
 ;;=^5009460
 ;;^UTILITY(U,$J,358.3,38951,0)
 ;;=I83.12^^151^1906^28
 ;;^UTILITY(U,$J,358.3,38951,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38951,1,3,0)
 ;;=3^Stasis Dermatitis.Left Leg
 ;;^UTILITY(U,$J,358.3,38951,1,4,0)
 ;;=4^I83.12
 ;;^UTILITY(U,$J,358.3,38951,2)
 ;;=^5007989
 ;;^UTILITY(U,$J,358.3,38952,0)
 ;;=I83.11^^151^1906^27
 ;;^UTILITY(U,$J,358.3,38952,1,0)
 ;;=^358.31IA^4^2
